About US
Contact us
-
Health Canada approves Otsuka and Lundbeck's once-monthly Abilify MaintenaHealth Canada has issued a notice of compliance for Otsuka and Lundbeck's Abilify Maintena, an intramuscular (IM) once-monthly injectable formulation, for the maintenance treatment of schizophrenia in2014/2/17
-
European Universities and companies partner in €85m antibiotics development projectMore than 30 European universities and companies, led by GlaxoSmithKline (GSK) and Uppsala University in Sweden, are joining forces in a €85m six-year programme funded by the Innovative Medicines Init2014/2/14
-
Health Canada approves Aegerion's JUXTAPID for homozygous familial hypercholesterolemia treatmentHealth Canada has granted a notice of compliance (NOC) approving Aegerion Pharmaceuticals' JUXTAPID, for treating a serious and rare genetic disease homozygous familial hypercholesterolemia (HoFH). J2014/2/14
-
Ario Pharma Commences Phase IIa Trial of TRPV1 Inhibitor for Cough Associated with COPDArio Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the t2014/2/13
-
Latin American Pharma Market Witnesses Increasing Investment, with Companies Looking to Further Operations in the RegionApproximately $12.7 billion has been invested in Latin America’s (LATAM’s) pharmaceutical market through mergers and acquisitions (M&As) in recent years, and with untapped potential identified in2014/2/13
-
Gilead submits NDA to US FDA for hepatitis C combination therapyGilead Sciences has filed a new drug application (NDA) with the US Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90mg and the nucleo2014/2/12
-
FDA accepts Spectrum Pharma's NDA filing for lymphoma drug BeleodaqThe US Food and Drug Administration (FDA) has accepted filing of Spectrum Pharmaceuticals' new drug application (NDA) for Beleodaq, a novel, pan-histone deacetylase (HDAC) inhibitor, intended for the2014/2/12
-
Alcobra seeks FDA's IND approval for Metadoxine extended-release to treat ADHDIsraeli biopharmaceutical company Alcobra has filed an investigational new drug (IND) application to the US Food and Drug Administration (FDA) to start a Phase III clinical trial with its proprietary2014/2/11
-
Omeros' Huntington's drug OMS824 gets FDA fast-track statusOmeros has received fast-track designation from the US Food and Drug Administration (FDA) for its phosphodiesterase 10 (PDE10) inhibitor 'OMS824' to treat cognitive impairment in patients with Hunting2014/2/11
-
NIH Study Finds Regular Aspirin use May Reduce Ovarian Cancer RiskWomen who take aspirin daily may reduce their risk of ovarian cancer by 20%, according to a study by scientists at the National Cancer Institute (NCI), part of theNational Institutes of Health. Howeve2014/2/10